Stoke Reports Q3 Results, Plans Zorevunersen NDA in H2 2027
Stoke said its Phase 3 EMPEROR trial remains on track, with about 110 of 162 patients at Week 28 and about 20 at Week 52; all continued into the open-label extension. The company plans a Phase 3 data readout in Q3 2027.
Stoke Therapeutics reported Q3 2026 results and said Phase 3 EMPEROR remains on track with ~110 of 162 patients at Week 28 and ~20 at Week 52; all continued into OLE. The company plans a Phase 3 data readout in Q3 2027 and to submit an NDA in H2 2027.Material DetailsContext by AI AnalystThis is mid…